Tag: VRTX

On February 5, 2024, Vertex Pharmaceuticals made a groundbreaking announcement regarding their Phase 3 pivotal trials of the vanzacaftor/tezacaftor/deutivacaftor (vanza ...

Vertex Pharmaceuticals has recently revealed promising results from its Phase 3 program for VX-548, a selective NaV1.8 inhibitor designed to ...